Search
Debbie Palmer BSc BND PhD Head, Nutrition in Early Life debbie.palmer@uwa.edu.au Head, Nutrition in Early Life Areas of research expertise: Maternal
Physical activity can support physical and mental health among children living with chronic health conditions; however, programmes must be tailored to their specific needs to support participation.
Eleven researchers from The Kids Research Institute Australia will benefit from the latest round of Stan Perron Charitable Foundation Research Fellowship and Platform grants, with two researchers receiving prestigious Perron Platform grants and a further ten awarded Research Fellowships.
As Neurodiversity Celebration Week draws to a close, we are shining a light on an important study underway at The Kids Research Institute Australia, led by Dr Thom Nevill, a Research Officer within our Human Development and Community Wellbeing and Child Disability teams.
Aboriginal families across Western Australia are being equipped with the knowledge to take early action against potentially life-threatening skin infections thanks to the launch of a Strong Skin phone app.
Researchers at The Kids Research Institute Australia hope an Australian-first nasal spray vaccine for two to 11-year-olds will boost flu vaccination this winter.
Timo Lassmann BSc (Hons) MSc PhD Feilman Fellow; Head, Precision Health Research and Head, Translational Intelligence timo.lassmann@thekids.org.au
The estimated effectiveness of SMS (short message service) reminders for improving childhood vaccine coverage and timeliness has varied in previous studies. The observed heterogeneity in effectiveness may be explained in part by variation in reminder content or timing of the reminder relative to the vaccine schedule date. We sought to evaluate the effectiveness of a range of SMS reminders of varied content and timing for improving on-time childhood vaccination.
Enteroviruses (EVs) have long been implicated in the development of islet autoimmunity (IA) and type 1 diabetes. However, given the ubiquity of EV infections in children, disease susceptibility is likely driven by host-specific immune responses rather than viral exposure alone.
The first peanut oral immunotherapy (OIT) for children was approved by the US Food and Drug Administration (FDA) in 2020. While clinical efficacy is established, evidence on cost-effectiveness-whether the benefits outweigh the costs and adverse effects-remains limited. A variant of OIT, known as probiotic and peanut OIT (PPOIT), has shown similar efficacy in trials.